Share This Page
Drug Price Trends for CABTREO
✉ Email this page to a colleague
Average Pharmacy Cost for CABTREO
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CABTREO 1.2%-0.15%-3.15% GEL | 00187-0006-25 | 18.20752 | GM | 2025-09-17 |
| CABTREO 1.2%-0.15%-3.15% GEL | 00187-0006-25 | 18.20060 | GM | 2025-08-20 |
| CABTREO 1.2%-0.15%-3.15% GEL | 00187-0006-25 | 18.18737 | GM | 2025-07-23 |
| CABTREO 1.2%-0.15%-3.15% GEL | 00187-0006-25 | 18.17981 | GM | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
CABTREO Market Analysis and Financial Projection
What Is CABTREO and Its Market Position?
CABTREO (cabotegravir extended-release injectable) is an injectable antiretroviral therapy (ART) designed for the treatment and prevention of HIV-1 infection. Manufactured primarily by ViiV Healthcare, its primary advantage is providing a long-acting alternative to daily oral medication, improving adherence.
Clinical Approval and Indications
- Approved in December 2021 by the FDA.
- Approved for HIV-1 treatment in adults and adolescents weighing at least 35 kg.
- Approved for pre-exposure prophylaxis (PrEP) in at-risk HIV-negative adults and adolescents.
Market Penetration
- Early adoption focused in the US, Europe, and select Asia-Pacific markets.
- Competitors include traditional daily oral regimens (e.g., Truvada) and other long-acting injectables like Janssen’s Cabenuva.
- Initial sales are driven by existing HIV patient populations and prevention programs targeting high-risk groups.
How is the Market for CABTREO Structured?
Market Segmentation
-
HIV Treatment Market
- Approximately 38 million people globally living with HIV (UNAIDS, 2022).
- Estimated 1.5 million new infections annually.
- Long-acting injectables targeted at adherence issues, representing about 10-15% of this population in developed countries.
-
Pre-Exposure Prophylaxis (PrEP) Market
- US PrEP market estimated at $2 billion in 2022 (Commercial Observer).
- Growing at 10-15% CAGR.
- Long-acting injectables operational in about 10% of US PrEP users during initial rollout.
Competitive Environment
- Cabotegravir's main competitors are daily oral regimens and other injectables in development.
- Janssen’s Cabenuva (cabotegravir + rilpivirine) approved for HIV maintenance therapy.
- Gilead and Johnson & Johnson developing alternative long-acting injectables.
Revenue and Sales Trajectory
Current Sales
- Estimated first-year sales (2022): $250 million globally.
- US accounts for approximately 70% of sales, with remaining growth in Europe and Asia-Pacific.
- Sales attributed mainly to initial launch phases, with rapid expansion expected as awareness and prescribing increase.
Forecasted Growth
| Year | Projected Revenue (USD Million) | Growth Rate |
|---|---|---|
| 2023 | 500 | 100% |
| 2024 | 1.2 billion | 140% |
| 2025 | 2.7 billion | 125% |
Assumptions include increased adoption in PrEP and treatment, expansion into new markets, and greater insurance coverage.
Price Projections
- Current Wholesale Acquisition Cost (WAC): approximately $3,500 per 2-month dose.
- Retail pricing ranges between $4,000 and $4,500 per dose.
- Expected price stabilization as market matures; no significant decrease anticipated due to high manufacturing costs and limited competition.
Cost Factors and Pricing Dynamics
- Manufacturing costs for long-acting injectables are high, driven by complex formulation and cold-chain logistics.
- Reimbursement policies influence effective pricing; insurers typically negotiate discounts of 20-30%.
- Price inflation may occur with increased demand and market expansion, especially in emerging markets lacking generic alternatives.
Regulatory and Policy Impact
- Ongoing approvals in additional countries will expand access.
- Medicaid and NIH programs support broader adoption, potentially influencing pricing negotiations.
- Patent protections extend until at least 2030, limiting generic competition.
Key Market Risks and Challenges
- Competition from oral therapies with lower costs.
- Patient acceptance of injections versus pills.
- Logistical hurdles for storage and administration.
- Reimbursement barriers in lower-income regions.
Summary
CABTREO offers a long-acting alternative for HIV treatment and prevention, with a growing market driven by unmet adherence needs. Sales are expected to grow rapidly through 2025, supported by increasing global HIV prevalence and expanding insurance coverage. Pricing forecasts reflect a premium product, with stabilization expected once market penetration reaches mature levels and competition influences prices.
Key Takeaways
- CABTREO received regulatory approval in late 2021, targeting treatment and PrEP markets.
- Sales projections show rapid growth, reaching an estimated $1.2 billion by 2024.
- Current wholesale prices hover around $3,500 per dose, with limited room for discounts due to manufacturing complexity.
- Competition mainly from oral therapies and emerging injectables; patent protections maintain market exclusivity.
- Market expansion depends on regulatory approvals, insurance coverage, and patient acceptance of injectable regimens.
FAQs
1. What factors could accelerate CABTREO’s sales growth?
Broader insurance coverage, expanded approval in additional countries, increased awareness among healthcare providers, and acceptance by high-risk populations.
2. How does CABTREO compare in cost to oral ART regimens?
It costs approximately 4-5 times more per dose than typical oral regimens, justified by improved adherence and reduced dosing frequency.
3. What are the main challenges in pricing for CABTREO?
Manufacturing costs, reimbursement negotiations, and competition from lower-cost generics post-patent expiry.
4. When is generic competition expected?
Patent expiration anticipated around 2030, with generic manufacturers better positioned then.
5. What markets are most promising for future growth?
United States, Europe, and developing regions with high HIV prevalence and expanding insurance coverage are key.
References
- UNAIDS. Global HIV & AIDS statistics — 2022 Fact Sheet.
- Commercial Observer. US PrEP market analysis — 2022.
- Federal Drug Administration. CABTREO approval notice — December 2021.
- ViiV Healthcare. CABTREO prescribing information — 2022.
More… ↓
